Market Overview

UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals to Perform on Near-Term Outlook

Related OPTR
HSR Waiting Period Expires for Cubist, Optimer Deal
Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M

Oppenheimer reduced its rating on Optimer Pharmaceuticals (NASDAQ: OPTR) from Outperform to Perform.

Oppenheimer noted, "We are downgrading shares of OPTR on the deceleration of DIFICID script growth which may be partially attributable to the availability of generic Vancocin. Longer term, scripts may be adversely impacted post expiration of the CBST co- promote agreement in 4/2013."

Optimer Pharmaceuticals closed at $11.46 on Monday.

Latest Ratings for OPTR

DateFirmActionFromTo
Jul 2013Canaccord GenuityDowngradesBuyHold
Jul 2013JefferiesDowngradesBuyHold
May 2013NeedhamDowngradesBuyHold

View More Analyst Ratings for OPTR
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (OPTR)

Around the Web, We're Loving...

Get Benzinga's Newsletters